Balentine LLC’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Balentine LLC’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-46	Closed	-$3K	–	671
2017 Q3	$3K	Sell	46 -27	-37%	-$2.91K	﹤0.01%	590
2017 Q2	$9K	Sell	73 -1	-1%	-$116	﹤0.01%	455
2017 Q1	$8K	Hold	74	–	–	﹤0.01%	440
2016 Q4	$8K	Buy	74 +11	+17%	+$1.31K	﹤0.01%	429
2016 Q3	$10K	Sell	63 -4	-6%	-$631	﹤0.01%	365
2016 Q2	$10K	Buy	+67	New	+$9.77K	﹤0.01%	356

Other funds holding ICPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Balentine LLC's ICPT Position: Q4 2017 in Review

Balentine LLC sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2017, closing a stake of 46 shares — an estimated $3K sold.

Balentine LLC first reported a position in ICPT in Q2 2016 and held it in 6 quarters. The position peaked at $10K in Q3 2016. 168 funds tracked by Wall St. Rank hold ICPT as of Q4 2017.

Balentine LLC reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
Balentine LLC sold 46 Intercept Pharmaceuticals, Inc. shares in Q4 2017, an estimated $3K.
Balentine LLC first reported a position in Intercept Pharmaceuticals, Inc. in Q2 2016 and held it in 6 quarters.
Balentine LLC's Intercept Pharmaceuticals, Inc. position peaked at $10K in Q3 2016.
168 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2017.

Based on Balentine LLC's 13F filing for Q4 2017, filed 14 Feb 2018.